思力华能倍乐的价格

On May 26, 2017, Boehringer Ingelheim announced the results of a new analysis that provides further evidence that respiratory symptoms improved after the addition of AZA in a Phase III clinical development program and in a population of patients whose asthma symptoms remained uncontrolled on daily maintenance therapy. The results of these data analyzes were presented at the American Thoracic Society (ATS) International Conference in Washington, D.C., USA.

The landmark TIOSPIRTM trial verified that Respimat 2.5μg (once daily, 2 puffs) and HandiHaler 18μg have similar safety and effectiveness. Both dosage forms of Respimat are in a leading position in the maintenance treatment of COPD.

Since there is no domestic listing information for Sliva Respimat yet, you need to consult Medical Companion Travel for the specific price.

The highly anticipated results of the 3-year trial were finally published (September 8, 2013) in the New England Journal of Medicine. The TIOSPIR trial was designed to compare the relative safety and efficacy of SRIVA RESPIMATO 2.5 μg (once daily, 2 puffs) and the investigational SRIVA RESPIMA dose 1.25 μg (once daily, 2 puffs) with SLIVA RESPIMA 18 μg. The specially designed TIOSPIR trial has appropriate sample size and follow-up time to analyze all-cause mortality and time to first acute exacerbation of COPD in a large population of COPD patients, and has broad inclusion criteria to truly reflect the real-world COPD patient population.

In the results discussion section, Professor Antonio Anzueto, professor of respiratory/emergency medicine at the University of Texas Health Science Center and trial investigator, said: "TIOSPIR is a landmark clinical trial that provides a large sample database to verify the safety of tiotropium bromide regardless of whether it is used with Sutra or Respimat, and once again confirms the safety of the drug. Safety and efficacy. More importantly, this large and carefully designed clinical trial evidence shows that tiotropium is safe in a wide range of COPD patients, including those with a history of heart disease. The key message from this large-scale TIOSPIR is that physicians can feel confident in choosing this proven treatment for maintenance patients with all levels of COPD.”

Adopting innovative technology, it is a new generation of effective SRIVA inhalers that patients can use under the advice of their doctor.

Recommended related hot articles: /newsDetail/82283.html